Wherefore art Tau?  Developing Methods for the Qualitative Interpretation of Tau PET

Presenter: John Seibyl, M.D. | Distinguished Scientist, Invicro

Tau PET  imaging is now commonly incorporated as an imaging biomarker in clinical research trials in Alzheimer’s and other tauopathies, particularly regarding serial longitudinal change in the evaluation of therapeutics designed to slow the course of disease. Both qualitative and quantitative assessments provide useful corroborative reporting endpoints.

The methods which operationalize these outcome measures, based on an understanding of the dynamic pathophysiology of brain tau deposition and its phenomenological manifestations on the PET scan are described for different tau radiopharmaceuticals, along with implications for future clinical and clinical research applications.

In this webinar, the presenter will:

  • Describe the differences between Amyloid and Tau PET with regard to pathophysiology and differing roles in clinical research trials
  • Describe the methodology and its validation for performing the visual interpretation of different Tau PET imaging agents
  • Explain the advantages and disadvantages of quantitative versus qualitative Tau PET assessments for questions posed in clinical research

Register for On-Demand Access:



Distinguished Scientist,  Invicro

Dr. Seibyl is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. Dr. Seibyl is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Marek, he has directed and continues to direct several international multicenter imaging studies. Dr. Seibyl is an author on over hundred publications on CNS imaging.